Intellia Therapeutics, Inc. develops and commercializes gene editing therapies using CRISPR technology. The company focuses on creating potentially curative treatments for severe diseases, including hereditary angioedema and ATTR amyloidosis, through both in vivo and ex vivo approaches. Intellia operates as a biopharmaceutical company, managing the entire process from drug discovery to commercialization, and collaborates with strategic partners to expand its therapeutic pipeline and address unmet medical needs globally.
